SCHEMBL18282199

SCHEMBL18282199

Cc1cc2sc(=S)[nH]c2c(C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 7/20 0.41
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 2/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 3/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GFER P55789 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
DYRK1A Q13627 1/20 0.33
CRHBP P24387 1/20 0.30
CRHR2 Q13324 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11335850 0.73 MAPT (0.48) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL8781343 0.67 PSMB8 (0.46) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL8781282 0.64 ALDH1A1 (0.51) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL13740465 0.64 PSMB8 (0.38) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL11478869 0.63 ALDH1A1 (0.60) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL17941559 0.62 PSMB8 (0.61) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL10967929 0.61 PSMB8 (0.59) PSMB8KDM4EALDH1A1HPGDCYP3A4
SCHEMBL15985836 0.60 MAPT (0.45) KDM4EALDH1A1HPGDALOX15TDP1
SCHEMBL31211377 0.59 LMNA (0.36) KDM4EALDH1A1HPGDCYP3A4MEN1
SCHEMBL31218445 0.59 HSD17B10 (0.36) KDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753418-B2 Compounds for the modulation of Myc activity SYROS PHARMACEUTICALS, INC. (US) 2023-09-12 US disclosed
US-11753418-B2 Compounds for the modulation of Myc activity SYROS PHARMACEUTICALS, INC. (US) 2023-09-12 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20220048927-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2022-02-17 US disclosed
US-11124527-B2 Compounds for the modulation of Myc activity SYROS PHARMACEUTICALS, INC. (US) 2021-09-21 US disclosed
US-11124527-B2 Compounds for the modulation of Myc activity SYROS PHARMACEUTICALS, INC. (US) 2021-09-21 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-20180354972-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-12-13 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
WO-2016196910-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed
WO-2016196910-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753418-B2 Compounds for the modulation of Myc activity MYC, MYCBP, MYCBP2 PSMB8 2716/4885KDM4E 4591/4885ALDH1A1 2514/4885
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 PSMB8 2678/4885KDM4E 4565/4885ALDH1A1 2091/4885
US-20220048927-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 PSMB8 2716/4885KDM4E 4591/4885ALDH1A1 2514/4885
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 PSMB8 2989/4885KDM4E 4623/4885ALDH1A1 2768/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 PSMB8 2989/4885KDM4E 4623/4885ALDH1A1 2768/4885
US-20180354972-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 PSMB8 2716/4885KDM4E 4591/4885ALDH1A1 2514/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 PSMB8 2678/4885KDM4E 4565/4885ALDH1A1 2091/4885
US-11124527-B2 Compounds for the modulation of Myc activity MYC, MYCBP, MYCBP2 PSMB8 2716/4885KDM4E 4591/4885ALDH1A1 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.